Investigational Drug Details
| Drug ID: | D151 |
| Drug Name: | Cyclophosphamide |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00531 |
| DrugBank Description: | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. |
| PubChem ID: | 2907 |
| CasNo: | 50-18-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | ClCCN(CCCl)P1(=O)NCCCO1 |
| Structure: |
|
| InChiKey: | CMSMOCZEIVJLDB-UHFFFAOYSA-N |
| Molecular Weight: | 261.086 |
| DrugBank Targets: | DNA; Nuclear receptor subfamily 1 group I member 2 |
| DrugBank MoA: | Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. |
| DrugBank Pharmacology: | Cyclophosphamide is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. |
| DrugBank Indication: | Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1121 | NCT01650012 | COMPLETED | NO | 2013-03 | 2015-09-28 | Details | |
| L1801 | NCT03811548 | PHASE3 | UNKNOWN | NO | 2019-05-23 | 2020-07-16 | Details |
| L3608 | NCT04321395 | PHASE2 | COMPLETED | YES | 2021-08-23 | 2025-01-14 | Details |
| L3733 | NCT04373967 | PHASE3 | UNKNOWN | NO | 2020-04-29 | 2020-07-08 | Details |
| L3761 | NCT02773368 | PHASE3 | COMPLETED | YES | 2016-05-23 | 2020-08-11 | Details |
| L3823 | NCT06411210 | PHASE2 | RECRUITING | NO | 2024-07-16 | 2024-07-23 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|